FDA Approves New Drug to Combat Severe Chronic Eczema

Injectable medication will be available within weeks.

The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The U.S. Food and Drug Administration approved a new monthly injectable drug that may benefit people with moderate to severe eczema.

EBGLYSS, developed by Eli Lilly, offers relief where other therapies have fallen short, potentially helping patients as young as 12 who have battled this chronic skin condition, the company said.